Home » BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies
BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies
BioMarin Pharmaceutical announced the initiation of a Phase I trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May